Nanobiotix S.A. Annual Report - How They Did This Year

I have reviewed the 2025 annual report for Nanobiotix S.A. to help you understand where the company stands. Because this is a clinical-stage biotech company, you should view it differently than a standard retail or tech business. They are not focused on immediate profit. Instead, they focus on hitting clinical milestones that prove their technology works.

Here is the breakdown of the latest update:

1. What does this company do and how did they perform?

Nanobiotix acts like an architect for cancer treatments. Their flagship technology, NBTXR3, is a radioenhancer. Doctors inject it into solid tumors to amplify the energy of radiation therapy, turning the tumor into a "Trojan horse" to destroy cancer cells without harming the rest of the body. This year, they focused on their global Phase 3 study (NANORAY-3) for head and neck cancer and managed their high-profile partnership with Janssen Pharmaceutica NV, a Johnson & Johnson company. The company filed its annual report (Form 20-F) with the SEC on April 29, 2025.

2. Financial performance

In biotech, revenue usually comes from milestone payments from partners rather than product sales. For 2024, Nanobiotix reported €6.2 million in revenue, primarily driven by the Janssen collaboration. The company is in a heavy investment phase, reporting an operating loss of €78.5 million as they prioritized research and development; in fact, research costs accounted for 75% of their total spending. As of December 31, 2024, they had 48.4 million shares outstanding and continue to rely on outside funding to operate.

3. Major wins and challenges

The core of the company's strategy is the Janssen partnership signed in July 2023, which is worth up to $1.8 billion in potential milestone payments. The company has been focused on managing technical transfers and hitting the specific goals required by this deal. Additionally, they finalized the termination of a legacy agreement with PharmaEngine, Inc., which allows Nanobiotix to reclaim full global rights to NBTXR3 and simplify their commercial strategy.

4. Financial health

Nanobiotix operates in a high-burn environment. At the end of 2024, they held approximately €45 million in cash. They fund operations through equity, royalty financing, and a €40 million loan from the European Investment Bank. Having utilized the final portions of that loan, the company expects their current cash to last into the second half of 2026.

5. Key risks

The primary risk is the "all-or-nothing" nature of clinical trials. If the NANORAY-3 trial fails to meet its primary goal, the stock could drop significantly, as the company’s value is almost entirely tied to the success of NBTXR3. Furthermore, they rely heavily on their partners; if Janssen ends the collaboration, it would severely impact Nanobiotix’s funding, development timelines, and long-term viability.

6. Future outlook

The next year is all about execution. They are moving through clinical trials, specifically targeting the interim analysis of the NANORAY-3 study, while meeting the technical requirements of their Janssen agreement. Keep a close eye on announcements regarding trial results, regulatory filings, and milestone payments. These are the "green lights" that drive the stock price.

Investor Takeaway: When watching this company, ignore traditional profit metrics. Instead, track the progress of the NANORAY-3 clinical trial and any official updates regarding the Janssen partnership. These two factors are the primary drivers of the company's future value.